Marina Biotech Appoints Amit Shah as Chief Financial Officer

City of Industry, CA – October 5, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Amit Shah will join the company in the newly created role of Chief Financial Officer, effective immediately. Prior to joining Read More

Windlas Healthcare Invests $2 Million in Working Capital to Support Marina Biotech’s Manufacturing Initiatives

City of Industry, CA  August 21, 2017 – Marina Biotech, Inc. (OTCQB: MRNAD) (‘Marina’ or the ‘Company’) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that its manufacturing partner, Windlas Healthcare Limited (‘Windlas’), has agreed to invest $2 million in working Read More

Marina Biotech Announces 1-for-10 Reverse Stock Split in Preparation for Proposed Up-Listing of its Common Stock to the NASDAQ Capital Market

City of Industry, CA  August 2, 2017 – Marina Biotech, Inc. (OTCQB: MRNA) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced a 1-for-10 reverse split of its common shares. The reverse split will be effective on the opening of trading on Read More

Marina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery Platform

City of Industry, CA  July 25th, 2017 – Marina Biotech, Inc. (OTCQB: MRNA) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that it has entered into a binding letter of intent with a biotech company in the gene editing space for Read More

Marina Biotech Acquires DyrctAxess™ Technology Platform to Support Sales and Marketing of Prestalia®

City of Industry, CA – July 24, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that it has acquired DyrctAxess™ Technology Platform from Symplmed Pharmaceuticals Inc.. DyrctAxess™ offers enhanced efficiency, control and information to Read More

Marina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics

City of Industry, CA  July 19th, 2017 – Marina Biotech, Inc. (OTCQB: MRNA) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that they have entered into a license agreement with Oncotelic, Inc. regarding the Company’s SMARTICLES™ platform for the delivery of Read More

Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman

Company Also Announces Closing of a Note Financing Led by Dr. Trieu and Dr. Hwang, CSO.  CITY OF INDUSTRY, CA – Jul 5, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that Dr. Vuong Trieu, has been Read More

Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia®

Company to narrow its business focus to pain and hypertension; Company plans to sell or divest the oligonucleotide therapeutic assets. CITY OF INDUSTRY, CA – Jun 26, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Read More

Marina Biotech Acquires Prestalia®, a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy

City of Industry, CA – June 6, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that it has acquired Prestalia®, a treatment of hypertension, from Symplmed Pharmaceuticals Inc.. Hypertension remains a significant health issue Read More

Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases

City of Industry, CA – May 30, 2017 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it will be presenting two poster presentations at the 22nd Annual Meeting of the RNA Society being held Read More

Scroll Up